1-9 of 9
Stacy L. Moulder
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer

Clinton Yam, Nour Abuhadra, Ryan Sun, Beatriz E. Adrada, Qing-Qing Ding, Jason B. White, Elizabeth E. Ravenberg, Alyson R. Clayborn, Vicente Valero, Debu Tripathy, Senthilkumar Damodaran, Banu K. Arun, Jennifer K. Litton, Naoto T. Ueno, Rashmi K. Murthy, Bora Lim, Luis Baez, Xiaoxian Li, Aman U. Buzdar, Gabriel N. Hortobagyi, Alistair M. Thompson, Elizabeth A. Mittendorf, Gaiane M. Rauch, Rosalind P. Candelaria, Lei Huo, Stacy L. Moulder, Jeffrey T. Chang
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2878–2889.
https://doi.org/10.1158/1078-0432.CCR-21-3100
Published: 01 July 2022
View article titled, Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer
Open the PDF for Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer

Clinton Yam, Er-Yen Yen, Jeffrey T. Chang, Roland L. Bassett, Jr, Gheath Alatrash, Haven Garber, Lei Huo, Fei Yang, Anne V. Philips, Qing-Qing Ding, Bora Lim, Naoto T. Ueno, Kasthuri Kannan, Xiangjie Sun, Baohua Sun, Edwin Roger Parra Cuentas, William Fraser Symmans, Jason B. White, Elizabeth Ravenberg, Sahil Seth, Jennifer L. Guerriero, Gaiane M. Rauch, Senthil Damodaran, Jennifer K. Litton, Jennifer A. Wargo, Gabriel N. Hortobagyi, Andrew Futreal, Ignacio I. Wistuba, Ryan Sun, Stacy L. Moulder, Elizabeth A. Mittendorf
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5365–5375.
https://doi.org/10.1158/1078-0432.CCR-21-0144
Published: 01 October 2021
View article titled, Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer
Open the PDF for Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer

Iman Doostan, Cansu Karakas, Mehrnoosh Kohansal, Kwang-Hui Low, Matthew J. Ellis, John A. Olson, Jr., Vera J. Suman, Kelly K. Hunt, Stacy L. Moulder, Khandan Keyomarsi
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (23): 7288–7300.
https://doi.org/10.1158/1078-0432.CCR-17-1544
Published: 30 November 2017
View article titled, Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer
Open the PDF for Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC)

Stacy L. Moulder, Virginia F. Borges, Tara Baetz, Tessa Mcspadden, Gina Fernetich, Rashmi K. Murthy, Renae Chavira, Kari Guthrie, Emma Barrett, Stephen K. Chia
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (14): 3529–3536.
https://doi.org/10.1158/1078-0432.CCR-16-1496
Published: 13 July 2017
View article titled, Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2<sup>+</sup>-Advanced Solid Tumors, with an Expansion Cohort in HER2<sup>+</sup> Metastatic Breast Cancer (MBC)
Open the PDF for Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2<sup>+</sup>-Advanced Solid Tumors, with an Expansion Cohort in HER2<sup>+</sup> Metastatic Breast Cancer (MBC) in another window
Journal Articles

Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer

Christos Hatzis, W. Fraser Symmans, Ya Zhang, Rebekah E. Gould, Stacy L. Moulder, Kelly K. Hunt, Maysa Abu-Khalaf, Erin W. Hofstatter, Donald Lannin, Anees B. Chagpar, Lajos Pusztai
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (1): 26–33.
https://doi.org/10.1158/1078-0432.CCR-14-3304
Published: 03 January 2016
View article titled, Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer
Open the PDF for Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer

Angela DeMichele, Douglas Yee, Donald A. Berry, Kathy S. Albain, Christopher C. Benz, Judy Boughey, Meredith Buxton, Stephen K. Chia, Amy J. Chien, Stephen Y. Chui, Amy Clark, Kirsten Edmiston, Anthony D. Elias, Andres Forero-Torres, Tufia C. Haddad, Barbara Haley, Paul Haluska, Nola M. Hylton, Claudine Isaacs, Henry Kaplan, Larissa Korde, Brian Leyland-Jones, Minetta C. Liu, Michelle Melisko, Susan E. Minton, Stacy L. Moulder, Rita Nanda, Olufunmilayo I. Olopade, Melissa Paoloni, John W. Park, Barbara A. Parker, Jane Perlmutter, Emanuel F. Petricoin, Hope Rugo, Fraser Symmans, Debasish Tripathy, Laura J. van‘t Veer, Rebecca K. Viscusi, Anne Wallace, Denise Wolf, Christina Yau, Laura J. Esserman
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (13): 2911–2915.
https://doi.org/10.1158/1078-0432.CCR-14-1760
Published: 30 June 2015
View article titled, The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer
Open the PDF for The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer in another window
Journal Articles

Phase I/II Study of G3139 (Bcl-2 Antisense Oligonucleotide) in Combination with Doxorubicin and Docetaxel in Breast Cancer

Stacy L. Moulder, W. Fraser Symmans, Daniel J. Booser, Timothy L. Madden, Cindy Lipsanen, Linda Yuan, Abenaa M. Brewster, Massimo Cristofanilli, Kelly K. Hunt, Thomas A. Buchholz, James Zwiebel, Vicente Valero, Gabriel N. Hortobagyi, Francisco J. Esteva
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (23): 7909–7916.
https://doi.org/10.1158/1078-0432.CCR-08-1104
Published: 01 December 2008
View article titled, Phase I/II Study of G3139 (Bcl-2 Antisense Oligonucleotide) in Combination with Doxorubicin and Docetaxel in Breast Cancer
Open the PDF for Phase I/II Study of G3139 (Bcl-2 Antisense Oligonucleotide) in Combination with Doxorubicin and Docetaxel in Breast Cancer in another window
Journal Articles

A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer

Carlos L. Arteaga, Anne O'Neill, Stacy L. Moulder, Michael Pins, Joseph A. Sparano, George W. Sledge, Nancy E. Davidson
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (19): 6277–6283.
https://doi.org/10.1158/1078-0432.CCR-08-0482
Published: 30 September 2008
View article titled, A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer
Open the PDF for A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer in another window
Journal Articles

A Phase I Open Label Study of the Farnesyltransferase Inhibitor CP-609,754 in Patients with Advanced Malignant Tumors

Stacy L. Moulder, John J. Mahany, Richard Lush, Caio Rocha-Lima, Michael Langevin, Karen J. Ferrante, Lisa Michele Bartkowski, Shama M. Kajiji, Dennis A. Noe, Simone Paillet, Daniel M. Sullivan
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (21): 7127–7135.
https://doi.org/10.1158/1078-0432.CCR-04-0901
Published: 08 November 2004
View article titled, A Phase I Open Label Study of the Farnesyltransferase Inhibitor CP-609,754 in Patients with Advanced Malignant Tumors
Open the PDF for A Phase I Open Label Study of the Farnesyltransferase Inhibitor CP-609,754 in Patients with Advanced Malignant Tumors in another window